Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12987810 | 0.78 | NOTUM (0.36) | PTGS2PTGS1NOTUMKCNH2RIPK1 | |
| SCHEMBL13193708 | 0.75 | PTGS1 (0.48) | PTGS2PTGS1NR3C2NOTUMRIPK1 | |
| SCHEMBL8925539 | 0.75 | NR3C2 (0.49) | PTGS2PTGS1NR3C2KCNH2 | |
| SCHEMBL6341689 | 0.72 | PTGS2 (0.89) | PTGS2PTGS1KCNH2 | |
| SCHEMBL8689349 | 0.72 | PTGS2 (0.51) | PTGS2PTGS1NR3C2NOTUMRIPK1 | |
| SCHEMBL8924318 | 0.71 | PTGS2 (0.63) | PTGS2PTGS1NR3C2 | |
| SCHEMBL8689354 | 0.70 | PTGS2 (0.64) | PTGS2PTGS1NR3C2 | |
| SCHEMBL6722795 | 0.70 | NR3C2 (0.52) | PTGS2PTGS1NR3C2 | |
| SCHEMBL6722182 | 0.70 | NR3C2 (0.49) | PTGS2PTGS1NR3C2KCNH2 | |
| SCHEMBL12987148 | 0.69 | CLK1 (0.38) | NOTUMKCNH2NPC1RAB9ACTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238026-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-01-19 | — | — | US | disclosed |
| US-9238026-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-01-19 | — | — | US | disclosed |
| US-9238026-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-01-19 | — | — | US | disclosed |
| US-20140128383-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-05-08 | — | — | US | disclosed |
| US-20140128383-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-05-08 | — | — | US | disclosed |
| US-20140128383-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-05-08 | — | — | US | disclosed |
| WO-2012137181-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128383-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | POLRMT, MAVS, EIF2AK2 | PTGS2 3278/4885PTGS1 2796/4885NR3C2 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.